注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶？ 登入
🎉 618領先一步，提前解鎖六月AI精選股！ 年中特惠
- 晨星評級:
- 總資產: 2.46B
Eventide Gilead I
48.83
-0.23
-0.47%
ETILX綜觀
你可在本頁找到深入的Eventide Gilead Class I公司檔案，包括ETILX的主要管理層、總資產、投資策略及聯絡資料，以及各類其他資訊。
聯絡資訊
主要管理層
| 名稱 | 主旨 | 成立於 | 直至 |
|---|---|---|---|
| Anant Goel | Portfolio Manager | 2022 | now |
| 自傳 | Anant Goel serves as Portfolio Manager for the Eventide Exponential Technologies Fund and Senior Research Analyst on other Eventide funds. Mr. Goel has a diverse background having grown up and lived in India, Hong Kong, UK, USA and China, which combined with his academic and professional interests, allow him to incorporate a diverse set of perspectives in his investment decision process. He has been passionate about responsible investing from early in his career. He has served as a Research Analyst at Eventide since 2016, leading its technology focused research. In 2015, during his M.B.A. program, he worked at Adage Capital Management, a long/short hedge fund. From 2011-2014, he served as an Analyst for NewQuest Capital Partners, a Private Equity firm in Hong Kong, where he was responsible for evaluating new investment opportunities for funds across Asia. From 2008-2011, he lived and worked in Beijing, China where he studied Mandarin and worked on start-up companies and other investment projects. Mr. Goel holds an M.B.A. from the MIT Sloan School of Management where he was selected as a Teaching Assistant (TA) for finance courses for both Executive M.B.A. and M.B.A. students. He also holds a Bachelors of Science (HONS) from the University of Warwick, UK in Economics. | ||
| Finny Kuruvilla | Resident | 2008 | now |
| 自傳 | Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s mid-cap growth and healthcare & life sciences strategies, a Managing Director for Eventide’s private fund, as well as Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech. | ||
| David Barksdale | Portfolio Manager | 2010 | 2018 |
| 自傳 | Mr. Barksdales has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and tactical asset allocation. He holds a bachelor's degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis. Prior to joining the portfolio management team in 2008, Mr. Barksdale served as a Senior Services Manager with Cadence Design Systems, an information technology company, from October 2005 until November 2008. | ||
在留言中加插圖表
確認封鎖
你確定要封鎖 %USER_NAME%？
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖，必須等候 48 小時後才可再次封鎖。
舉報此評論
我覺得這個評論是:
評論被加標記
謝謝！
您的報告已被發送到我們的版主審核